Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cardiology and Cardiovascular Medicine,Pharmacology,General Medicine
Reference59 articles.
1. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355(3):251–9.
2. Kass KS, DA. Unmet needs in cardiovascular science and medicine: heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. CircRes. 2012;40(6):1301–15.
3. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011;32(6):670–9.
4. Li R, Shan Y, Gao L, Wang X, Wang X, Wang F. The GLP-1 analog liraglutide protects against angiotensin II and pressure overload-induced cardiac hypertrophy via PI3K/AKT1 and AMPKa signaling. Front Pharmacol. 2019;10:1–15.
5. Nguyen TD, Shingu Y, Amorim PA, Schenkl C, Schwarzer M, Doenst T. GLP-1 improves diastolic function and survival in heart failure with preserved ejection fraction. J Cardiovasc Transl Res. 2018;11(3):259–67.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献